Article
Phenotypic Screening Using Patient-Derived Induced Pluripotent Stem Cells Identified Pyr3 as a Candidate Compound for the Treatment of Infantile Hypertrophic Cardiomyopathy.
International heart journal - 26 Sept 2018
Sakai Taku, Naito Atsuhiko T, Kuramoto Yuki, Ito Masamichi, Okada Katsuki, Higo Tomoaki, Nakagawa Akito, Shibamoto Masato, Yamaguchi Toshihiro, Sumida Tomokazu, Nomura Seitaro, Umezawa Akihiro, Miyagawa Shigeru, Sawa Yoshiki, Morita Hiroyuki, Lee Jong-Kook, Shiojima Ichiro, Sakata Yasushi, Komuro Issei
Abstract excerpt
Hypertrophic cardiomyopathy (HCM) is a genetic disorder that is characterized by hypertrophy of the myocardium. Some of the patients are diagnosed for HCM during infancy, and the prognosis of infantile HCM is worse than general HCM. Nevertheless, pathophysiology of infantile HCM is less investigated and remains largely unknown. In the present study, we generated induced pluripotent stem cells (iPSCs) from two...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.